Remibrutinib Resolves Chronic Inducible Urticaria Symptoms

Written by The Life Science Feed Editorial Team · Published 17 June 2026 · Edited by William Lopes

Chronic inducible urticaria (CIndU) presents a significant burden for patients, characterised by recurrent hives, angioedema, and pruritus triggered by specific physical stimuli. Current management often involves antihistamines, which may not provide complete symptom control for all patients. The introduction of remibrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, offers a targeted therapeutic approach for this challenging condition.

KEY TAKEAWAYS

- The Pivot: Remibrutinib, a BTK inhibitor, provides a targeted non-antihistamine option for chronic inducible urticaria.
- The Data: Remibrutinib demonstrated complete resolution of CIndU symptoms in a significant proportion of patients.
- The Action: Clinicians should consider remibrutinib for patients with CIndU who have inadequate response to standard antihistamine therapy.

Chronic inducible urticaria (CIndU) is a form of urticaria where hives, angioedema, or both are triggered by specific physical stimuli, such as cold, pressure, or heat. This condition can severely impact quality of life, with symptoms often refractory to standard antihistamine regimens. The underlying pathophysiology involves mast cell activation and degranulation, releasing histamine and other inflammatory mediators. Bruton's tyrosine kinase (BTK) plays a critical role in mast cell signalling pathways, making it a viable therapeutic target for conditions driven by mast cell activation. CIndU encompasses several distinct subtypes, including cold urticaria, delayed pressure urticaria, heat urticaria, solar urticaria, symptomatic dermographism, and vibratory urticaria. Each subtype is defined by its specific trigger, leading to a diverse clinical presentation. The prevalence of CIndU is estimated to be around 1% of the general population, with symptomatic dermographism being the most common subtype. Patients often experience significant distress due to the unpredictable nature of their symptoms and the limitations imposed on their daily activities, ranging from avoiding certain environments to difficulty performing occupational tasks.

The trial

Clinical trials evaluated the efficacy and safety of remibrutinib, an oral, highly selective BTK inhibitor, in patients with chronic inducible urticaria. These studies enrolled patients diagnosed with CIndU who had experienced symptoms for at least six months and had an inadequate response to H1-antihistamines at up to four times the standard dose. Patients were randomised to receive either remibrutinib or placebo. The primary endpoints typically focused on the change in

disease activity scores, such as the Urticaria Activity Score (UAS7) or specific inducible urticaria activity scores, and the proportion of patients achieving complete symptom resolution. Secondary endpoints often included improvements in quality of life measures, such as the Dermatology Life Quality Index (DLQI), and the assessment of safety and tolerability through adverse event reporting and laboratory parameter monitoring. The rigorous inclusion criteria ensured that the study population represented individuals with significant, persistent CIndU symptoms despite conventional treatment, highlighting the unmet medical need addressed by these trials. Patient populations included adults across a broad age range, reflecting the typical demographic affected by CIndU.

In a Phase IIb study, patients with chronic spontaneous urticaria (CSU), a related condition, treated with remibrutinib 25 mg twice daily demonstrated a significant reduction in weekly urticaria activity scores compared to placebo. The mean change from baseline in UAS7 at week 12 was -20.9 for remibrutinib versus -10.4 for placebo ($p < 0.001$). A higher proportion of patients receiving remibrutinib achieved a UAS7 score of 0 or 1 (complete or near-complete symptom control) compared to placebo. While this study focused on CSU, the mechanistic action of BTK inhibition on mast cells is relevant to CIndU given the shared pathophysiology of mast cell activation. The selectivity of remibrutinib for BTK is crucial, as it aims to minimize off-target effects that could lead to broader immunosuppression or other systemic adverse events. This selectivity contributes to a more favorable safety profile compared to less specific inhibitors.

Further studies specifically in CIndU populations have shown similar trends. For example, in a study of cold urticaria, patients treated with remibrutinib achieved complete resolution of inducible symptoms, as measured by a negative cold stimulation test, in a significantly higher proportion than those on placebo. The cold stimulation test involves applying a cold object to the skin for a defined period and observing for the development of hives, providing an objective measure of disease activity. Similar objective provocation tests were employed for other CIndU subtypes to assess treatment efficacy.

The safety profile of remibrutinib across these trials indicated it was generally well-tolerated. The most commonly reported adverse events were mild to moderate and included headache, nasopharyngitis, and diarrhoea. No unexpected safety signals or significant liver enzyme elevations were observed, which is a consideration with some other BTK inhibitors. The duration of these trials typically extended over several months, allowing for the assessment of sustained efficacy and the emergence of any delayed adverse events. Limitations of the studies often included the relatively small sample sizes for specific CIndU subtypes, which can limit the generalizability of findings across the entire spectrum of inducible urticarias. Additionally, the long-term efficacy and safety beyond the trial periods require further investigation.

The sustained efficacy observed in these trials suggests that remibrutinib offers a promising therapeutic option for patients with CIndU who have not achieved adequate control with antihistamines. The oral administration route also provides a convenient alternative to injectable biologics. The precise mechanism by which remibrutinib achieves symptom resolution involves inhibiting BTK, thereby blocking downstream signalling pathways essential for mast cell activation and degranulation, reducing the release of inflammatory mediators responsible for urticarial symptoms. This targeted approach represents a significant advancement in the management of CIndU, moving beyond symptomatic relief to address a core pathological mechanism. The convenience of an oral medication can also improve patient adherence and overall treatment experience compared to therapies requiring injections.

For a comprehensive understanding of urticaria and other skin conditions, readers may consult the excellent Oxford Handbook of Medical Dermatology.

CLINICAL IMPLICATIONS

The emergence of remibrutinib as an effective treatment for chronic inducible urticaria marks a significant step forward for patients who have long struggled with refractory symptoms. For general practitioners and specialists, this provides a much-needed oral alternative to existing therapies, particularly for those patients who do not respond adequately to high-dose antihistamines or who are not candidates for omalizumab. The convenience of an oral medication could improve adherence and patient satisfaction, reducing the burden of frequent clinic visits for injections.

From an industry perspective, the development of highly selective BTK inhibitors like remibrutinib highlights a strategic shift towards more targeted therapies in inflammatory and autoimmune conditions. This precision medicine approach, focusing on specific molecular pathways, offers the potential for improved efficacy with a more favourable safety profile compared to broader immunosuppressants. The competitive landscape in urticaria treatment is evolving, and companies investing in oral, targeted therapies are likely to gain market share, especially if long-term safety data remains reassuring.

Patients suffering from chronic inducible urticaria often experience substantial impairment to their daily lives, affecting everything from social activities to professional performance. The prospect of complete symptom resolution, as demonstrated in trials, offers genuine hope. It means fewer unpredictable episodes of hives and angioedema, less pruritus, and ultimately, a better quality of life. The availability of an effective oral treatment could empower patients to manage their condition more autonomously, reducing the psychological distress often associated with chronic, unpredictable diseases.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Kaul M, et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14(5):1756-1768. doi:10.1111/cts.13005
2. 2. Mendes-Bastos P, et al. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022;77(8):2355-2366. doi:10.1111/all.15261

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED